Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 257-267 , September 2010

Identifying early prescribers of Cycloxygenase-2 Inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing

  • Kent E.M. Groves, B.Sc., M.Sc., Ph.D.

      Affiliations

    • College of Pharmacy, Dalhousie University, 5968 College St., Halifax NS B3H 3J5 Canada
    • Healthcare Strategy Group, Merkle Inc, Columbia, MD 21046 USA
    • Corresponding Author InformationCorresponding author. College of Pharmacy, Dalhousie University 5968 College St., Halifax NS Canada B3H 3J5. Tel.: +902 476 0872; fax: +902 482 3459.
  • ,
  • Tony Schellinck, B.Sc., M.B.A., Ph.D.

      Affiliations

    • Faculty of Management, Dalhousie University, 6100 University Avenue, Halifax, NS Canada B3H 3J5
  • ,
  • Ingrid Sketris, Pharm.D., M.P.A. (HSA)

      Affiliations

    • College of Pharmacy, Dalhousie University, 5968 College St., Halifax NS B3H 3J5 Canada
  • ,
  • Neil J. MacKinnon, B.Sc. (Pharm.), M.S., Ph.D.

      Affiliations

    • College of Pharmacy, Dalhousie University, 5968 College St., Halifax NS B3H 3J5 Canada

References 

  1. Canadian Institute for Health Information. http://secure.cihi.ca/cihiweb/products/Drug_Expenditure_in_Canada_1985_2007_e.pdfAccessed November 10, 2008
  2. Greenhalgh T, Robert G, MacFarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581–629
  3. Foxall G. Consumer choice as an evolutionary process: an operant interpretation of adopter behavior. Adv Consum Res. 1994;21:312–317
  4. Assael H. Consumer Behavior and Marketing Actions. 2nd ed. Boston, MA: Kent Publishing Company; 1983;443–956
  5. Gatignon H, Roberston TS. A propositional inventory for new diffusion research. J Consum Res. 1985;11:849–869
  6. McDonald H, Corkindale D, Sharp B. Behavioral versus demographic predictors of early adoption: a critical analysis and comparative test. J Market Theor Pract. 2003;11(4):84–95
  7. Dybdahl T, Andersen M, Sondergaard J, Kragstrup J, Kristiansen IS. Does the early adopter of drugs exist? A population-based study of general practitioners' prescribing of new drugs. Eur J Clin Pharmacol. 2004;60:667–672
  8. Kozyrskyj A, Raymond C, Racher A. Characterizing early prescribers of newly marketed drugs in Canada: a population based study. Eur J Clin Pharmacol. 2007;63:597–604
  9. Rogers EM. Diffusion of Innovations. New York, NY: The Free Press; 1983;
  10. Groves K, Flanagan P, MacKinnon N. Why physicians start or stop prescribing a drug: literature review and formulary implications. Formulary. 2002;37:186–194
  11. Nova Scotia Department of Health. Nova Scotia seniors' pharmacare information. 2008. www.gov.ns.ca/health/pharmacareAccessed October 20, 2008
  12. IMS Health Canada. Canadian Disease and Therapeutic Index. IMS Health: Kirkland, PQ; 2005;
  13. Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med. 2006;36:308–319
  14. Hawkey CJ. COX-2 chronology. Gut. 2005;54:1509–1514
  15. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307–314
  16. Health Canada. Health Canada Informs Canadians of Vioxx® Withdrawal by Merck & Co., 2004; http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2004/2004_50-eng.php, Accessed October 21, 2008.
  17. Nielsen OH, Ainsworth M, Csillag C, Rask-Madsen J. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. Aliment Pharmacol Ther. 2006;23:27–33
  18. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442
  19. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008;64:233–252
  20. Curtiss FR. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam. J Manag Care Pharm. 2006;12:265–268
  21. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther. 2008;33:1–10
  22. Lado E, Vacariza M, Fernández-González C, Gestal-Otero JJ, Figueiras A. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study. J Eval Clin Pract. 2008;14:453–459
  23. Dybdahl T, Andersen M, Kragstrup J, Kristiansen IS, Søndergaard J. General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. Br J Clin Pharmacol. 2005;60:526–533
  24. Sketris IS, Metge CJ, Ross JL, MacCara ME. The use of the World Health Organisation anatomical therapeutic chemical/defined daily dose methodology in Canada. Drug Inf J. 2004;38:15–27
  25. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data. Theoretical considerations and practical applications. Eur J Clin Pharmacol. 2000;56:513–517
  26. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17:20–24
  27. Bearden WO, Etzel MJ. Reference group influence on product and brand purchase decisions. J Consum Res. 1982;9:183–194
  28. Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract. 1999;16:407–413
  29. Cranney M, Warren E, Barton S, Gardner K, Walley T. Why do GPs not implement evidence-based guidelines? A descriptive study. Fam Pract. 2001;18:359–363
  30. Groves KEM, MacKinnon NJ, Sketris IS. Prescribing behavior. In:  Rickles NM,  Wertheimer AI,  Smith MC editor. Social and Behavioral Aspects of Pharmaceutical Care. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers; 2009;p. 141–176

PII: S1551-7411(09)00108-9

doi: 10.1016/j.sapharm.2009.09.003

Research in Social and Administrative Pharmacy
Volume 6, Issue 3 , Pages 257-267 , September 2010